Alex Brill Joins Panel Discussion on Tax Policy in the Build Back Better Act
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
Pension Smoothing – The Budget Gimmick That Will Not Die
The bipartisan infrastructure bill approved by the Senate on August 10 includes a number of budget gimmicks that help make it look fully “paid for.” One of the gimmicks is pension smoothing, which allows private companies to make smaller contributions to their defined-benefit pension plans, thereby endangering the plans’ financial viability over time.
Alex Brill Interviewed on Future of US Biosimilars Market
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.
Carbon Tax vs. Corporate Tax | In 60 Seconds
Democrats want to increase the corporate tax rate, but is that the best way to generate revenue for the government? AEI’s Alex Brill discusses an alternative tax that could benefit the planet as well.
MGA’s Christy Robinson Quoted in IAM Article on Patent Thickets
In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. Featured in the article is MGA’s report on patent thickets, as well as a quote from MGA’s Christy Robinson, who voiced her concern regarding the future of the biosimilars market.
- Current and Future State of US Biosimilars
- Trends in the US Insulin Market: New Prices, New Players, New Dynamics
- Implications of Cannabis Legalization for the US Federal Budget
- Biden Budget Proposes a Step Toward Biologic Drug Competition
- MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
- The Next Tax Fight: SALT
- Alex Brill on Single-Payer Health Care System and Drug Costs
- New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
- The Threat to Preferred Pharmacy Networks
